Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

The bromodomain and extraterminal (BET) protein BRD2-4 inhibitors hold therapeutic promise in preclinical models of hematologic malignancies. However, translation of these data to molecules suitable for clinical development has yet to be accomplished. Herein we expand the mechanistic understanding o...

Full description

Bibliographic Details
Main Authors:	Chaidos, A, Caputo, V, Gouvedenou, K, Liu, B, Marigo, I, Chaudhry, M, Rotolo, A, Tough, D, Smithers, N, Bassil, A, Chapman, t, Harker, N, Barbash, O, Tummino, P, Al-Mahdi, N, Haynes, A, Cutler, L, Le, B, Rahemtulla, A, Roberts, I, Kleijnen, M, Witherington, J, Parr, N, Prinjha, R, Karadimitris, A
Format:	Journal article
Language:	English
Published:	American Society of Hematology 2014

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

Similar Items